Replagal (agalsidase alfa) was approved by Health Canada in 2004 and indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
Amicus Therapeutics is currently developing migalastat, an oral drug designed to bind to and stabilize the α‐Gal A that is made in the patient’s own cells, with the intention of enabling its trafficking to lysosomes.